

## Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

Roland B. Walter,<sup>1,2</sup> Bruno C. Medeiros,<sup>3</sup> Bayard L. Powell,<sup>4</sup> Charles A. Schiffer,<sup>5</sup> Frederick R. Appelbaum,<sup>1,6</sup> and Elihu H. Estey<sup>1,2</sup>

<sup>1</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; <sup>2</sup>Department of Medicine, Division of Hematology, University of Washington, Seattle, WA; <sup>3</sup>Stanford University, Stanford, CA; <sup>4</sup>Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC; <sup>5</sup>Barbara Ann Karmanos Cancer Center, Wayne State University, Detroit, MI; and <sup>6</sup>Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA

*Citation: Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica 2012;97(5):739-742. doi:10.3324/haematol.2011.055822*

Online Supplementary Table S1. Tolerability and Safety of Study Therapy.

Parameter	Grade 3-4	Grade 5
Blood/Bone Marrow		
Anemia	8	--
Neutropenia	21	--
Thrombocytopenia	19	--
Hemorrhage/Bleeding		
Epistaxis	1	--
Gastrointestinal Bleed	2	--
Other	1	--
Fever, Infection		
Neutropenic Fever	13	--
Documented Infection	5	1
Pneumonia	3	--
Cardiac		
Hypertension	1	--
Suspected NSTEMI*	1	--
Renal		
Acute Renal Failure	2	--
Metabolic		
Hypokalemia	1	--
Hyperglycemia	1	--
Allergy		
Dyspnea	3	--
Constitutional		
Weight loss	1	--
Pain		
Headache	1	--
Gastrointestinal		
Nausea	1	--
Gastrointestinal Fistula	1	--
Other		
Fall	1	--

\*Non-STSegment Elevation Myocardial Infarction.